We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Cutting Edge Technology Used to Grade Cancer Tumors

By LabMedica International staff writers
Posted on 28 Mar 2018
Biopsy specimens are processed into formalin-fixed-paraffin-embedded (FFPE) blocks and currently, hematoxylin and eosin (H + E) stained sections are widely used for the histopathological diagnosis of cancer and other pathologies.

Typically the sections are graded subjectively by eye, using disease-specific grading protocols. More...
Histological grading of breast cancer currently varies widely across multiple institutions and practitioners, because it relies on subjective criteria. However an analysis of  more than 24, 000 biopsies, graded by 732 breast cancer graders, found that they only agreed ~73% of the time on average.

A team of scientists from Imperial College London (London, UK) carried out a double-blind clinical pilot trial using two adjacent slices taken from 75 breast cancer biopsies. The patients were all female with ages ranging from 30.4 to 83.7, mean age 58.7 at diagnosis. More than half of the samples were grade 2 tumors (54.3%). The majority were HER2 negative (90.0%). The first slice was graded by clinicians as usual, using the standard H+E protocol. It was also used to identify the so-called 'region of interest' (RoI), i.e. the part of the slice containing the tumor.

The team used their new 'Digistain' technology addresses the problem of consensus among pathologists by using invisible mid-infrared light to photograph the tissue slices in a way that maps out the chemical changes that signal the onset of cancer. In particular, they measure the 'nuclear-to-cytoplasmic-ratio' (NCR): a recognized biological marker for a wide range of cancers. The team then used the Digistain imager to get a 'Digistain index' (DI) value averaged over the corresponding RoI on the other, unstained slice, and ran a statistical analysis on the results.

The DI measures the concentration ratios of phosphodiester to amide moieties, and because these are dominantly related to the amounts of nuclear and cytoplasmic material, respectively, The DI images can be regarded as 2D maps of the nuclear-to-cytoplasmic ratio, (NCR). The NCR factor that ‘Digistain’ measures is known to be common to a wide range of cancers, as it occurs when the reproductive cell cycle gets disrupted in the tumor and cell nuclei get distorted with rogue DNA. It is likely that in the long run, Digistain could help with the diagnosis of all different types of cancer. At a practical level, the team reported that the Digistain imaging technology can easily and cheaply be incorporated into existing hospital laboratories, and be used by their staff.

Chris Phillips, PhD, a Professor of Experimental Solid State Physics and lead investigator of the study, said, “Our machine gives a quantitative 'Digistain index' (DI) score, corresponding to the NCR, and this study shows that it is an extremely reliable indicator of the degree of progression of the disease. Because it is based on a physical measurement, rather than a human judgement, it promises to remove the element of chance in cancer diagnosis.” The study was published on March 13, 2018, in the journal Convergent Science Physical Oncology.

Related Links:
Imperial College London


Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Drug Test Kit
DrugCheck 3000
New
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Molecular Diagnostics

view channel
Image: The RNA-seq based diagnostic test for pediatric leukemia ensures better outcomes for children with this common cancer (Photo courtesy of Qlucore)

RNA-Seq Based Diagnostic Test Enhances Diagnostic Accuracy of Pediatric Leukemia

A new unique test is set to reshape the way Acute Lymphoblastic Leukemia (BCP-ALL) samples can be analyzed. Qlucore (Lund, Sweden) has launched the first CE-marked RNA-seq based diagnostic test for pediatric... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.